Angsuman Chakraborty11 Jul 2008 08:02 am
Opexa Therapeutics, Inc. has announced today the Data Safety Monitoring Board (DSMB) has recommended the trial of Tovaxin to continue unmodified. Opexa Therapeutics, Inc. is the company that develops cell therapies for multiple sclerosis. This positive recommendation follows a regularly scheduled meeting of the DSMB in June and is based upon an evaluation of clinical, magnetic resonance imaging (MRI) and safety data that had been recorded for all patients to date.
The TERMS trial (Tovaxin for Early Relapsing Multiple Sclerosis) is nearing completion and the DSMB has two additional scheduled meetings in July and August of this year. Tovaxin is being evaluated in a multi-center, randomized, double blind, placebo controlled study in 150 patients suffering from Relapse Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS).
It can be added that Tovaxin is an individualized T-cell therapeutic vaccine that consists of attenuated patient-specific myelin-reactive T-cells (MRTCs) against peptides of proteins from Myelin basic protein (MBP), Myelin oligodendrocyte glycoprotein (MOG) and Proteolipid protein (PLP) or combinations thereof. Recently, two-year follow up data from Phase I/II clinical studies of 22 patients showed 73% of patients on Tovaxin remained relapse free after two years with 86% experiencing no disease progression. Tovaxin is manufactured in Opexa’s in-house cGMP facility.
The Company’s(Opexa) lead product is Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte-derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection.
Source:foxbusiness
Filed under Multiple Sclerosis, Stem Cell | Comment Below
Related?
Stem Cell Tranasplant for Chemo-Radiation Therapy or Chemotherapy Recovery: Phase I Clinical Trial CompletedJuly 24th, 2006 ViaCell, Inc. today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up.
Bio-heart Trial Using Myocell Myoblast Cells Proves SuccessfulMay 8th, 2008 Bio-heart has finally revealed the data of its seismic trial. It shows that Myocell Myoblast clinical cell therapy is good way to improve heart problems like cardiac devices and congested heart diseases.
Stem cell therapy cured star footballer suffering from "Multiple Sclerosis"February 12th, 2009 A huge score of U.S. population suffer from the dreaded chronic degenerative disorder named Multiple Sclerosis (MS).
Stem cell transplantation shows positive results to treat Multiple SclerosisMay 11th, 2009 A National Institutes of Health (NIH)-sponsored study called HALT-MS confirms, high-dose immunosuppression followed by autologous stem cell transplantation will prevent MS attacks in patients who are not responding to available treatment options and ultimately protect against the degeneration of nerve fibers. In this summer edition, 2009 of Multiple Sclerosis Quarterly Report, a joint publication of United Spinal Association (www.UnitedSpinal.org) and the North American Research Committee on Multiple Sclerosis (NARCOMS), highlights the positive initial results of patients who have improving neurologic function after receiving a stem cell transplant, despite no longer taking any MS medications.
Stem Cell Product Trial to Treat Heart Attack Receives FDA Clearance May 10th, 2007 Australia's adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks. The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission.
Stem Cell Therapeutics Phase IIb trials for stroke patients achieves FDA approvalMay 14th, 2009 U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to Stem Cell Therapeutics Corp.(SCT) to commence the recruitment of stroke patients under an amended protocol using NTx®-265 for the Company's Phase IIb clinical trial for the acute ischemic stroke treatment. The company is expecting the written approval from FDA in near future.
Stem Cell Trial for Heart Attack Approved by FDAMay 7th, 2007 Australia's adult stem cell company, Mesoblast Limited has announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company,
Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks. The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission.
Stem Cell Therapy Shows Slight Relief for Multiple Sclerosis PatientJanuary 31st, 2007 AN Oakenshaw man who received treatment in Germany for Multiple Sclerosis before Christmas has noticed a slight improvement in his sight. Gary Mayrick received controversial stem cell treatment at a clinic in Cologne in October and was told not to expect an immediate improvement in his condition.
Leave a Comment
Opexa Therapeutics, Inc. has announced today the Data Safety Monitoring Board (DSMB) has recommended the trial of Tovaxin to continue unmodified. Opexa Therapeutics, Inc. is the company that develops cell therapies for multiple sclerosis. This positive recommendation follows a regularly scheduled meeting of the DSMB in June and is based upon an evaluation of clinical, magnetic resonance imaging (MRI) and safety data that had been recorded for all patients to date.
